Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

8th Eurasian Hematology Oncology Summit
14:53

8th Eurasian Hematology Oncology Summit

Maintenance Therapy in AML: Overview of Outcomes and Future Approaches

FEATURING Tapan Kadia
  • 151 views
  • July 7, 2021
  • 1
13:09

8th Eurasian Hematology Oncology Summit

Brentuximab Vedotin in HL: Evaluating the Clinical Data

FEATURING Christian Gisselbrecht
  • 27 views
  • June 15, 2021
10:10

8th Eurasian Hematology Oncology Summit

The Role of MRD in AML: Navigating Testing Techniques & Prediction of Clinical Outcomes

FEATURING Tapan Kadia
  • 278 views
  • June 11, 2021
  • 1
19:17

8th Eurasian Hematology Oncology Summit

Treating Myelofibrosis in 2021: What Are the Efficacy Data for Ruxolitinib? Is Allo-HCT a Good Curative Option in Advanced Disease?

FEATURING Haifa Kathrin Al-Ali
  • 170 views
  • June 11, 2021
  • 1
19:08

8th Eurasian Hematology Oncology Summit

2021 Efficacy Data Review in Relapsed CLL: BTK Inhibitors, Ven+/-Rituximab, LOXO-305

FEATURING Susan O'Brien
  • 145 views
  • June 11, 2021
16:00

8th Eurasian Hematology Oncology Summit

Frontline Treatment of CLL: Surveying Outcomes With BTKi / BCL-2i Options

FEATURING Susan O'Brien
  • 61 views
  • June 4, 2021
  • 1
09:15

8th Eurasian Hematology Oncology Summit

How I Treat ET in 2021: WHO True-ET, Thromboembolic/Bleeding Complications, Risk of Thrombosis and Bleeding With COVID-19, Anagrelide, Peg-IFN, Platelet Goal

FEATURING Dominik Wolf
  • 34 views
  • May 13, 2021
10:04

8th Eurasian Hematology Oncology Summit

How I Treat PV in 2021: JAKi in Symptomatic Disease, Anti-Clonal Activity of PegIFN-Alpha, Phlebotomy&ASA +/- Ropeg-IFN Alpha-2b for Low-PV

FEATURING Dominik Wolf
  • 102 views
  • May 13, 2021
14:23

8th Eurasian Hematology Oncology Summit

Surveying the Data on DLBCL Treatments: RT Therapy in the PET Era, Intensive Chemotherapy, and Novel Agents

FEATURING Umberto Vitolo
  • 26 views
  • May 13, 2021
05:47

8th Eurasian Hematology Oncology Summit

R/R DLBCL: Novel Strategies in 1L/2L Treatment

FEATURING Umberto Vitolo
  • 142 views
  • May 13, 2021
06:03

8th Eurasian Hematology Oncology Summit

Novel Strategies in 1/2L Large Cell Lymphoma: Navigating Treatment Options for DLBCL, and (B-Cell) NHL

FEATURING Umberto Vitolo
  • 151 views
  • May 13, 2021
  • 1
07:18

8th Eurasian Hematology Oncology Summit

How Important Is Imaging (PET) for 1L Early Stage HL?

FEATURING Christian Gisselbrecht
  • 232 views
  • May 13, 2021
  • 2
21:14

8th Eurasian Hematology Oncology Summit

2021 Treatment Considerations for Follicular Lymphoma: Localized, Advanced, and R/R Cases

FEATURING Gianluca Gaidano
  • 202 views
  • May 13, 2021
  • 1
12:00

8th Eurasian Hematology Oncology Summit

Navigating Treatment Options for Newly Diagnosed ASCT-Eligible MM in 2021: Induction & Standard (VCD, VTD, VRd, Dara-VTD), Upfront ASCT vs. Bortezomib, Len Maintenance Until Progression

FEATURING Angelo Maiolino
  • 84 views
  • May 13, 2021
07:11

8th Eurasian Hematology Oncology Summit

Survival Data for Newly Diagnosed ASCT-Ineligible MM: VRd vs. Rd, VMP vs. D-VMP, D-Rd vs. Rd

FEATURING Angelo Maiolino
  • 13 views
  • May 13, 2021
21:36

8th Eurasian Hematology Oncology Summit

CAR-T Cell Therapy for Multiple Myeloma

FEATURING Evangelos Terpos
  • 145 views
  • May 13, 2021
  • 1
07:00

8th Eurasian Hematology Oncology Summit

MRD in CLL: What Were the Changes and Issues Over the Years? Is This the Disease of the Elderly?

FEATURING Robin Foa
  • 216 views
  • May 13, 2021
17:18

8th Eurasian Hematology Oncology Summit

2021 Updates on MRD in CLL: Chemoimmunotherapy vs. Targeted Approach; IGHV & TP53 Mutations

FEATURING Robin Foa
  • 128 views
  • May 13, 2021
  • 1
06:59

8th Eurasian Hematology Oncology Summit

2021 Oral HMAs Efficacy Data in MDS: Decitabine + Cedazuridine for HR Disease, Azacitidine for RBC-TD Anemia & Thrombocytopenia With LR Disease

FEATURING Guillermo Garcia-Manero
  • 77 views
  • May 13, 2021
15:42

8th Eurasian Hematology Oncology Summit

2021 MDS Highlights: Luspatercept for Very Low-Intermediate Risk, Imetelstat for R/R LR-Disease, Len in Non-TD LR Patients, Aza for TP53m, Nivo/Ipi +/- Aza, Aza & Pembro for HR-MDS, Ena for IDH2m

FEATURING Guillermo Garcia-Manero
  • 41 views
  • May 13, 2021
20:55

8th Eurasian Hematology Oncology Summit

2021 Lower Risk MDS Updates: RBC Transfusions, ESA in Anemia, Lenalidomide, Oral HMAs, Roxadustat, Imetelstat, Thrombocytopenia, TPO RA

FEATURING Moshe Mittelman
  • 62 views
  • May 13, 2021
13:39

8th Eurasian Hematology Oncology Summit

2021 Highlights on Higher Risk MDS: Can We Improve on Azacitidine? What Are the Options for High-Risk HMA Failure? How to Integrate alloSCT?

FEATURING Guillermo Garcia-Manero
  • 247 views
  • May 13, 2021
  • 2
25:12

8th Eurasian Hematology Oncology Summit

2021 Updates on TFR in CML: What Are the Factors and Best Predictors Involved in TFR Maintenance? What Are the Outcomes and MMR Loss After TKI Discontinuation?

FEATURING Giuseppe Saglio
  • 12 views
  • May 13, 2021
21:28

8th Eurasian Hematology Oncology Summit

How to Treat Newly Diagnosed AML in Unfit Patients: Pretreatment Testing, Intensive Therapy vs. Lower Intensity Therapy, FLT3/IDH-Mutated Options

FEATURING Tapan Kadia
  • 146 views
  • May 13, 2021
  • 1
08:17

8th Eurasian Hematology Oncology Summit

Highlights on ETP-ALL: Recognition, Role of Allogeneic Transplant, Combination Strategies, mAbs (Daratumumab)

FEATURING Sabina Chiaretti
  • 31 views
  • May 13, 2021
13:48

8th Eurasian Hematology Oncology Summit

Updates on Ph-Like ALL: Genomic Background, Diagnosis, Outcomes, and Therapy Approach

FEATURING Sabina Chiaretti
  • 105 views
  • May 13, 2021